Report Detail

Request for Sample of this report

Pharma & Healthcare Global and Japan Spinal Muscular Atrophy Medicine Market Insights, Forecast to 2026

  • RnM4199037
    • |
  • 10 September, 2020
    • |
  • Global
    • |
  • 145 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Spinal Muscular Atrophy Medicine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Spinal Muscular Atrophy Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Spinal Muscular Atrophy Medicine market is segmented into
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others

Segment by Application, the Spinal Muscular Atrophy Medicine market is segmented into
Hospital
Clinic
Others

Regional and Country-level Analysis
The Spinal Muscular Atrophy Medicine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Spinal Muscular Atrophy Medicine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Spinal Muscular Atrophy Medicine Market Share Analysis
Spinal Muscular Atrophy Medicine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Spinal Muscular Atrophy Medicine business, the date to enter into the Spinal Muscular Atrophy Medicine market, Spinal Muscular Atrophy Medicine product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.


1 Study Coverage

  • 1.1 Spinal Muscular Atrophy Medicine Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Spinal Muscular Atrophy Medicine Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type
    • 1.4.2 LMI-070
    • 1.4.3 ND-602
    • 1.4.4 NT-1654
    • 1.4.5 Nusinersen
    • 1.4.6 NXD-30001
    • 1.4.7 Others
  • 1.5 Market by Application
    • 1.5.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Application
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Spinal Muscular Atrophy Medicine Market Size, Estimates and Forecasts
    • 2.1.1 Global Spinal Muscular Atrophy Medicine Revenue 2015-2026
    • 2.1.2 Global Spinal Muscular Atrophy Medicine Sales 2015-2026
  • 2.2 Global Spinal Muscular Atrophy Medicine, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.3 Spinal Muscular Atrophy Medicine Historical Market Size by Region (2015-2020)
    • 2.3.1 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.3.2 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Revenue by Region: 2015-2020
  • 2.4 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Region (2021-2026)
    • 2.4.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2021-2026)
    • 2.4.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Region (2021-2026)

3 Global Spinal Muscular Atrophy Medicine Competitor Landscape by Players

  • 3.1 Global Top Spinal Muscular Atrophy Medicine Sales by Manufacturers
    • 3.1.1 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2015-2020)
    • 3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Global Spinal Muscular Atrophy Medicine Manufacturers by Revenue
    • 3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2015-2020)
    • 3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy Medicine Revenue in 2019
    • 3.2.5 Global Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Global Spinal Muscular Atrophy Medicine Price by Manufacturers
  • 3.4 Global Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Product Types
    • 3.4.1 Spinal Muscular Atrophy Medicine Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Spinal Muscular Atrophy Medicine Product Type
    • 3.4.3 Date of International Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Spinal Muscular Atrophy Medicine Market Size by Type (2015-2020)
    • 4.1.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2015-2020)
    • 4.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2015-2020)
    • 4.1.3 Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Type (2021-2026)
    • 4.2.3 Spinal Muscular Atrophy Medicine Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Spinal Muscular Atrophy Medicine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Spinal Muscular Atrophy Medicine Market Size by Application (2015-2020)
    • 5.1.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2015-2020)
    • 5.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2015-2020)
    • 5.1.3 Spinal Muscular Atrophy Medicine Price by Application (2015-2020)
  • 5.2 Spinal Muscular Atrophy Medicine Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Spinal Muscular Atrophy Medicine Price Forecast by Application (2021-2026)

6 Japan by Players, Type and Application

  • 6.1 Japan Spinal Muscular Atrophy Medicine Market Size YoY Growth 2015-2026
    • 6.1.1 Japan Spinal Muscular Atrophy Medicine Sales YoY Growth 2015-2026
    • 6.1.2 Japan Spinal Muscular Atrophy Medicine Revenue YoY Growth 2015-2026
    • 6.1.3 Japan Spinal Muscular Atrophy Medicine Market Share in Global Market 2015-2026
  • 6.2 Japan Spinal Muscular Atrophy Medicine Market Size by Players (International and Local Players)
    • 6.2.1 Japan Top Spinal Muscular Atrophy Medicine Players by Sales (2015-2020)
    • 6.2.2 Japan Top Spinal Muscular Atrophy Medicine Players by Revenue (2015-2020)
  • 6.3 Japan Spinal Muscular Atrophy Medicine Historic Market Review by Type (2015-2020)
    • 6.3.1 Japan Spinal Muscular Atrophy Medicine Sales Market Share by Type (2015-2020)
    • 6.3.2 Japan Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2015-2020)
    • 6.3.3 Japan Spinal Muscular Atrophy Medicine Price by Type (2015-2020)
  • 6.4 Japan Spinal Muscular Atrophy Medicine Market Estimates and Forecasts by Type (2021-2026)
    • 6.4.1 Japan Spinal Muscular Atrophy Medicine Sales Forecast by Type (2021-2026)
    • 6.4.2 Japan Spinal Muscular Atrophy Medicine Revenue Forecast by Type (2021-2026)
    • 6.4.3 Japan Spinal Muscular Atrophy Medicine Price Forecast by Type (2021-2026)
  • 6.5 Japan Spinal Muscular Atrophy Medicine Historic Market Review by Application (2015-2020)
    • 6.5.1 Japan Spinal Muscular Atrophy Medicine Sales Market Share by Application (2015-2020)
    • 6.5.2 Japan Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2015-2020)
    • 6.5.3 Japan Spinal Muscular Atrophy Medicine Price by Application (2015-2020)
  • 6.6 Japan Spinal Muscular Atrophy Medicine Market Estimates and Forecasts by Application (2021-2026)
    • 6.6.1 Japan Spinal Muscular Atrophy Medicine Sales Forecast by Application (2021-2026)
    • 6.6.2 Japan Spinal Muscular Atrophy Medicine Revenue Forecast by Application (2021-2026)
    • 6.6.3 Japan Spinal Muscular Atrophy Medicine Price Forecast by Application (2021-2026)

7 North America

  • 7.1 North America Spinal Muscular Atrophy Medicine Market Size YoY Growth 2015-2026
  • 7.2 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
    • 7.2.1 North America Spinal Muscular Atrophy Medicine Sales by Country (2015-2020)
    • 7.2.2 North America Spinal Muscular Atrophy Medicine Revenue by Country (2015-2020)
    • 7.2.3 U.S.
    • 7.2.4 Canada

8 Europe

  • 8.1 Europe Spinal Muscular Atrophy Medicine Market Size YoY Growth 2015-2026
  • 8.2 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
    • 8.2.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
    • 8.2.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country
    • 8.2.3 Germany
    • 8.2.4 France
    • 8.2.5 U.K.
    • 8.2.6 Italy
    • 8.2.7 Russia

9 Asia Pacific

  • 9.1 Asia Pacific Spinal Muscular Atrophy Medicine Market Size YoY Growth 2015-2026
  • 9.2 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
    • 9.2.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2015-2020)
    • 9.2.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region
    • 9.2.3 China
    • 9.2.4 Japan
    • 9.2.5 South Korea
    • 9.2.6 India
    • 9.2.7 Australia
    • 9.2.8 Taiwan
    • 9.2.9 Indonesia
    • 9.2.10 Thailand
    • 9.2.11 Malaysia
    • 9.2.12 Philippines
    • 9.2.13 Vietnam

10 Latin America

  • 10.1 Latin America Spinal Muscular Atrophy Medicine Market Size YoY Growth 2015-2026
  • 10.2 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
    • 10.2.1 Latin America Spinal Muscular Atrophy Medicine Sales by Country
    • 10.2.2 Latin America Spinal Muscular Atrophy Medicine Revenue by Country
    • 10.2.3 Mexico
    • 10.2.4 Brazil
    • 10.2.5 Argentina

11 Middle East and Africa

  • 11.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size YoY Growth 2015-2026
  • 11.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
    • 11.2.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country
    • 11.2.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country
    • 11.2.3 Turkey
    • 11.2.4 Saudi Arabia
    • 11.2.5 U.A.E

12 Company Profiles

  • 12.1 Astellas Pharma Inc.
    • 12.1.1 Astellas Pharma Inc. Corporation Information
    • 12.1.2 Astellas Pharma Inc. Description and Business Overview
    • 12.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered
    • 12.1.5 Astellas Pharma Inc. Recent Development
  • 12.2 AveXis, Inc.
    • 12.2.1 AveXis, Inc. Corporation Information
    • 12.2.2 AveXis, Inc. Description and Business Overview
    • 12.2.3 AveXis, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Products Offered
    • 12.2.5 AveXis, Inc. Recent Development
  • 12.3 Bioblast Pharma Ltd.
    • 12.3.1 Bioblast Pharma Ltd. Corporation Information
    • 12.3.2 Bioblast Pharma Ltd. Description and Business Overview
    • 12.3.3 Bioblast Pharma Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 12.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Products Offered
    • 12.3.5 Bioblast Pharma Ltd. Recent Development
  • 12.4 Cytokinetics, Inc. 24
    • 12.4.1 Cytokinetics, Inc. 24 Corporation Information
    • 12.4.2 Cytokinetics, Inc. 24 Description and Business Overview
    • 12.4.3 Cytokinetics, Inc. 24 Sales, Revenue and Gross Margin (2015-2020)
    • 12.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Products Offered
    • 12.4.5 Cytokinetics, Inc. 24 Recent Development
  • 12.5 F. Hoffmann-La Roche Ltd.
    • 12.5.1 F. Hoffmann-La Roche Ltd. Corporation Information
    • 12.5.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
    • 12.5.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 12.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Products Offered
    • 12.5.5 F. Hoffmann-La Roche Ltd. Recent Development
  • 12.6 Genethon
    • 12.6.1 Genethon Corporation Information
    • 12.6.2 Genethon Description and Business Overview
    • 12.6.3 Genethon Sales, Revenue and Gross Margin (2015-2020)
    • 12.6.4 Genethon Spinal Muscular Atrophy Medicine Products Offered
    • 12.6.5 Genethon Recent Development
  • 12.7 Genzyme Corporation
    • 12.7.1 Genzyme Corporation Corporation Information
    • 12.7.2 Genzyme Corporation Description and Business Overview
    • 12.7.3 Genzyme Corporation Sales, Revenue and Gross Margin (2015-2020)
    • 12.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Products Offered
    • 12.7.5 Genzyme Corporation Recent Development
  • 12.8 GMP-Orphan SAS
    • 12.8.1 GMP-Orphan SAS Corporation Information
    • 12.8.2 GMP-Orphan SAS Description and Business Overview
    • 12.8.3 GMP-Orphan SAS Sales, Revenue and Gross Margin (2015-2020)
    • 12.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Products Offered
    • 12.8.5 GMP-Orphan SAS Recent Development
  • 12.9 Ionis Pharmaceuticals, Inc.
    • 12.9.1 Ionis Pharmaceuticals, Inc. Corporation Information
    • 12.9.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
    • 12.9.3 Ionis Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Products Offered
    • 12.9.5 Ionis Pharmaceuticals, Inc. Recent Development
  • 12.10 Longevity Biotech, Inc
    • 12.10.1 Longevity Biotech, Inc Corporation Information
    • 12.10.2 Longevity Biotech, Inc Description and Business Overview
    • 12.10.3 Longevity Biotech, Inc Sales, Revenue and Gross Margin (2015-2020)
    • 12.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Products Offered
    • 12.10.5 Longevity Biotech, Inc Recent Development
  • 12.11 Astellas Pharma Inc.
    • 12.11.1 Astellas Pharma Inc. Corporation Information
    • 12.11.2 Astellas Pharma Inc. Description and Business Overview
    • 12.11.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.11.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered
    • 12.11.5 Astellas Pharma Inc. Recent Development
  • 12.12 Neurotune AG
    • 12.12.1 Neurotune AG Corporation Information
    • 12.12.2 Neurotune AG Description and Business Overview
    • 12.12.3 Neurotune AG Sales, Revenue and Gross Margin (2015-2020)
    • 12.12.4 Neurotune AG Products Offered
    • 12.12.5 Neurotune AG Recent Development
  • 12.13 Novartis AG
    • 12.13.1 Novartis AG Corporation Information
    • 12.13.2 Novartis AG Description and Business Overview
    • 12.13.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
    • 12.13.4 Novartis AG Products Offered
    • 12.13.5 Novartis AG Recent Development
  • 12.14 Sarepta Therapeutics, Inc.
    • 12.14.1 Sarepta Therapeutics, Inc. Corporation Information
    • 12.14.2 Sarepta Therapeutics, Inc. Description and Business Overview
    • 12.14.3 Sarepta Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.14.4 Sarepta Therapeutics, Inc. Products Offered
    • 12.14.5 Sarepta Therapeutics, Inc. Recent Development
  • 12.15 Voyager Therapeutics, Inc.
    • 12.15.1 Voyager Therapeutics, Inc. Corporation Information
    • 12.15.2 Voyager Therapeutics, Inc. Description and Business Overview
    • 12.15.3 Voyager Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.15.4 Voyager Therapeutics, Inc. Products Offered
    • 12.15.5 Voyager Therapeutics, Inc. Recent Development
  • 12.16 Vybion, Inc.
    • 12.16.1 Vybion, Inc. Corporation Information
    • 12.16.2 Vybion, Inc. Description and Business Overview
    • 12.16.3 Vybion, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 12.16.4 Vybion, Inc. Products Offered
    • 12.16.5 Vybion, Inc. Recent Development
  • 12.17 WAVE Life Sciences Ltd.
    • 12.17.1 WAVE Life Sciences Ltd. Corporation Information
    • 12.17.2 WAVE Life Sciences Ltd. Description and Business Overview
    • 12.17.3 WAVE Life Sciences Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 12.17.4 WAVE Life Sciences Ltd. Products Offered
    • 12.17.5 WAVE Life Sciences Ltd. Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Spinal Muscular Atrophy Medicine Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Spinal Muscular Atrophy Medicine Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Summary:
    Get latest Market Research Reports on Spinal Muscular Atrophy Medicine. Industry analysis & Market Report on Spinal Muscular Atrophy Medicine is a syndicated market report, published as Global and Japan Spinal Muscular Atrophy Medicine Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of Spinal Muscular Atrophy Medicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,900.00
    		$5,850.00
    		$7,800.00
    		3,108.30
    		4,662.45
    		6,216.60
    		3,627.00
    		5,440.50
    		7,254.00
    		596,232.00
    		894,348.00
    		1,192,464.00
    		325,377.00
    		488,065.50
    		650,754.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo